Introduction: The development of direct-acting antiviral (DAA) agents for the treatment of
hepatitis C virus (HCV) infection has completely transformed the management of this …

Background Direct‐acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection is
highly curative and tolerable. Among patients with hepatocellular carcinoma (HCC), optimal …

Methods We analyzed the Taiwan HCV Registry Program database to explore predictors of
DAA failure in HCV patients. Fifty-five host and virological features were assessed using …

Background: Despite an increasing burden of nonalcoholic steatohepatitis (NASH), limited
data are available comparing outcomes of NASH-related hepatocellular carcinoma (HCC) …

Hepatitis C virus (HCV) infection is prevalent among people in prison and prisons could
therefore represent a unique opportunity to test risk groups for HCV. The aim of this sero …

Introduction: Within the past decade, antiviral treatment for chronic hepatitis C virus (HCV)
infection has evolved from interferon (IFN)-based regimens to IFN-free oral direct-acting …

Objective The treatment outcome of direct-acting antivirals (DAAs) in chronic hepatitis C
patients with hepatocellular carcinoma (HCC) is controversial. The current study aimed to …

Direct-acting antivirals (DAA) regimens have provided hope for eliminating hepatitis C virus
(HCV) infection. Patients following ineffective therapy with DAA, especially those previously …

Background: The benefits of hepatitis C virus (HCV) eradication for hepatocellular
carcinoma (HCC) patients in Barcelona Clinic Liver Cancer (BCLC) stage B/C remain …

Introduction: Concerns were raised about a high occurrence of hepatocellular carcinoma
(HCC) after successful treatment of chronic hepatitis C (CHC) by direct-acting antivirals …